Part 1 - Case Presentation

Daniel A. Pollyea, MD, MS, presents the case of patient “A.B.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).

Click here to learn more by viewing Part 2 - Case Discussion.

Disclosures:

Brian A. Jonas, MD, PhD, FACP
Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda
Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC
Travel Reimbursement: AbbVie

Gabriel N. Mannis, MD
Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer
Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz

Daniel A. Pollyea, MD, MS
Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS
Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas

References:

  1. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. PMID: 25008258; PMCID: PMC4137593.
  2. Stone RM, Larson RA, Döhner H. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 Nov 9;377(19):1903. doi: 10.1056/NEJMc1711340. PMID: 29117486.